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Abstract 
Purpose 
Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in 
several tumour types and is, therefore, a promising anti-cancer approach. Although 
several Chk1 inhibitors have been developed, their clinical progress has been 
hampered by low bioavailability and off-target toxicities.  
Materials and Methods 
We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable 
Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and 
monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo 
models. 
Results 
CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth 
delay in cancer xenograft models associated with a survival benefit. Radiosensitization 
was elicited by abrogation of the radiation-induced G2 arrest and premature entry into 
mitosis.  
Conclusions 
CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It 
radiosensitizes tumour cell lines and represents a new therapy for clinical application in 
combination with radiotherapy 
 
 Introduction 
 
Despite significant advances in treatments for locally-advanced bladder and head and 
neck squamous cell cancers (HNSCC), the 5-year disease-specific survival rates are 
poor [1, 2]. Most patients receive radiotherapy (RT), either as primary 
RT/chemoradiotherapy (CRT) in an organ-sparing approach, or post-operatively, as 
adjuvant RT/CRT. Unfortunately, failure to achieve loco-regional disease control and 
significant radiation-induced treatment toxicities mean that outcomes are suboptimal in 
many patients.   
One strategy to improve the efficacy of RT is to target signaling pathways activated by 
radiation.  Chk1 is one of the main regulators of the G2/M checkpoint and an essential 
signal transducer in the cellular response to DNA damage and replication stress [3, 4]. 
Therefore, this kinase represents an attractive target for sensitizing cancer cells to both 
RT and chemotherapy. Previous studies have shown that selectively targeting the G2/M 
cell cycle checkpoint can improve cancer cell sensitivity to RT [5, 6]. A number of Chk1 
inhibitors have demonstrated tumour-specific radiosensitization in preclinical studies [7-
9].  However, their translation into clinical trials has been limited by difficulties with 
pharmaceutical formulation and toxicity. Here, we present data on CCT244747, a 
potent, non-toxic, orally bioavailable Chk1 inhibitor [10] that mediates in vitro and in vivo 
radiosensitization by modulating G2/M checkpoint control. We show that death occurs 
through mitotic catastrophe and/or apoptosis in cells cycling with unrepaired DNA 
damage. 
 
Materials and Methods 
 
Cell lines, drug treatment and irradiation 
RT112, T24 (bladder) and Cal27 (HNSCC) were obtained from ATCC.  hTertRPE1 
epithelial cells were obtained from Dr C. Bakal( ICR), London.  All cancer cell lines were 
typed using short tandem repeat analysis (Bio-Synthesis Inc., Texas, USA). Cells were 
cultured in 10% Foetal Bovine serum (FBS) (Gibco® by life technologies), 1% glutamine 
and 0.5% penicillin/streptomycin, in Dulbecco’s modified Eagle’s medium (DMEM) (ICR, 
London, UK) and routinely tested for mycoplasma. CCT244747 was synthesized by the 
ICR, Sutton and dissolved in dimethyl sulfoxide (DMSO) (Fisher Scientific) for in vitro 
experiments and in 10% DMSO, 5% Tween-80, 20% PEG400 (Sigma-Aldrich) and 65% 
H2O for in vivo experiments. Irradiation was carried out as previously described [7]. 
 
Clonogenic assays 
Cells were seeded into 6-well plates and, 16-24 hours later, treated with CCT244747 
(0.25 µM, 0.5 µM or 2 µM). Plates were irradiated (2, 4 or 6 Gy) 6 hours post-treatment 
with CCT244727. Medium was replaced 48 hours after treatment with CCT244747. 
Cells were fixed and stained using 5% glutaraldehyde and 0.05% crystal violet (Sigma-
Aldrich) 10-20 days after treatment. Colonies (≥50 cells) were counted manually.  
Surviving fractions were calculated as a ratio of the untreated control cells after 
normalizing for plating efficiency. Survival curves were generated using Prism 6, 
(GraphPad Software, San Diego, California, USA). Statistical differences were analysed 
with a 2-way ANOVA test. 
  
Cell cycle distribution 
Cells were seeded in 10 cm dishes and, 48 hours later, treated with 4 µM CCT244747. 
Plates were irradiated with 8 Gy in a single fraction 6 hours after exposure to 
CCT244747. Cells were fixed with 70% ethanol at indicated time points with 
CCT244747 and stained with pS10 histone H3 conjugated Alexa (R)647 antibody (Cell 
Signalling) and propidium iodide. Flow cytometry analysis was performed using a LSRII 
flow cytometer (BD Biosciences, Oxford, UK). 
 
Western blotting analysis 
Cells were seeded and treated with CCT244747 and radiation as described above.  
Whole-cell lysates were collected using radioimmunoprecipitation assay (RIPA) buffer at 
selected time-points after treatment with CCT244747. The following antibodies were 
used for western blotting: pS345 Chk1, total Chk1, Caspase-3, pS139 Histone H2A.X, 
β-Actin and GAPDH (Cell Signalling), PARP-1 (Santa Cruz Biotechnology) and pS10 
Histone H3 (Merck Millipore). 
 
Immunofluorescence analysis 
Cells were plated in 35 mm glass-bottomed, collagen-coated dishes (MatTek, 
Massachusetts, USA) and irradiated with 4 Gy 6 hours after treatment with 4 µM 
CCT244747. Cells were fixed with 4% formaldehyde at the indicated time points and 
immunofluorescence was performed as previously described [7].  Cells were stained 
with pS139 Histone H2A.X (ɣ-H2AX; Cell signaling) and α-Tubulin (Sigma Aldrich) and 
visualized using Alexafluor-488-conjugated goat anti-rabbit and Alexfluor-546-
conjugated goat anti-mouse antibodies (InvitrogenTM, Life technologies) along with 4’,6-
diamidino-2-phenylindole, dihydrochloride (DAPI; Invitrogen, Molecular Probes™) 
nuclear stain.  A minimum of 100 nuclei were examined.  Nuclei were quantified as 
positive for foci when ≥5 foci were present within the nucleus, positive for pan-nuclear 
staining when ≥80% of the nucleus was stained positive for ɣ-H2AX.  Micronucleated or 
multinucleated cells were scored as abnormal. 
 
 
In vivo studies 
Female 5- to 6-week-old athymic nude mice (CD-1® Nude Mouse Crl:CD1-Foxn1nu, 
Charles River) were used. All experiments were approved by the institutional review 
board in compliance with NCRI guidelines. 3×106 Cal27 cells were injected 
subcutaneously in the right flank. Once tumours had reached approximately 5 mm 
diameter, animals were randomized into 4 groups (n=8): control, RT, single-agent 
CCT244747 and CCT244747 plus RT. Radiotherapy consisted of a total dose of 10 Gy 
in 5 fractions on alternate days. CCT244747 (100 mg/kg) was administered by gavage 1 
hr before each radiation fraction [10]. Tumour volume was calculated as Volume = 
(Width2 x Length)/2).  Body weights were taken twice weekly.  The time taken to reach 
the experimental endpoint (tumour diameter >15 mm) in each group was compared by 
log-rank test. 
 
 
 
Results 
 
CCT244747 radiosensitizes bladder and head and neck cancer cell lines 
There was a significant difference between 0 and 2 Gy radiation when T24, RT112 and 
Cal27 cancer cells were treated with 0.5 µM CCT244747. This effect was not evident in 
hTertRPE1 epithelial cells (Fig 1a). The dose modifying factor (DMF) was calculated to 
quantify the degree of sensitisation (Fig S1 a,b). This showed a marked dose-modifying 
effect in T24, RT112 and Cal27 cancer cells that was not seen in hTertRPE1 epithelial 
cells, indicating cancer cell-specific radiosensitisation by CCT244747. 
 
The on-target effect of CCT244747 was evaluated using western blot analysis at 8 and 
12 hours after treatment with 4 µM CCT244747. CCT244747 induced phosphorylation 
at the Ser345 (pS345) site on Chk1, indicating increased DNA damage and protein 
phosphatase PP2A inhibition [11].  Radiation-induced pS345-Chk1 was evident in T24 
and RT112 cell lines, but not to the same extent as for single-agent CCT244747 
treatment.  Combining CCT244747 with radiation increased pS345-Chk1 above levels 
seen with CCT244747 alone in T24, RT112 and Cal27 (Fig. 1c).  
 
 
CCT244747 abrogates RT-induced G2 arrest 
To determine whether CCT244747 would modify radiation-mediated cell cycle changes, 
cells were treated with CCT244747 6 hours before irradiation.   To calculate the 
percentage of cells in mitosis, cells were stained for pS10-Histone H3 (p-HH3) and 
analyzed by flow cytometry.  Treatment with CCT244747 significantly abrogated 
radiation-mediated G2 arrest at 12 hours (Fig. 2a). This continued cell cycling following 
irradiation, due to the presence of CCT244747, led to a significant increase in the 
mitotic and G1 populations in RT112 and Cal27 cells at 12 hours and the S phase 
population in all cells lines at 24 hours (Fig. S2).  
 
All cell lines exhibited a significant increase in the G2 phase of the cell cycle and a 
decrease in the mitotic population at 6 hours post-irradiation (12 hour time point), 
indicating a DNA damage-induced G2 arrest (Fig 2a). Irradiation of cells with 8 Gy 
caused a decrease in the G1 population and a small increase in the S phase population 
at 12 hours after treatment. Both G1 and S phase populations were decreased in all cell 
lines at 24 hours post-irradiation (Fig S2).  
CCT244747 alone reduced the G2 population in T24 and Cal27 cells and the mitotic 
population in T24 cells at 12 hours. This effect was not seen in RT112 cells and had 
recovered in other cells by 24 hours (Fig. 2a).  There was also an observable increase 
in the S phase population in all cells 12 and 24 hours post-treatment with CCT244747 
(Fig S2). This increase in the S phase may represent Chk1-dependent stalled 
replication [3, 12].   
The flow cytometry results were confirmed by Western blotting for p-HH3, where a 
decrease in the expression of p-HH3 indicated G2 arrest. A dramatic reduction in the 
expression of p-HH3 was seen 6 hours after irradiation in all cell lines (12 hour time 
point) (Fig 2b). Treatment with CCT244747 abrogated radiation-mediated G2 arrest 
resulting in an increase in the expression of p-HH3 at 12-48 hours after treatment 
(compared to radiation alone).  
To examine whether cells were dying by apoptosis or becoming aneuploid 48 hours 
after treatment, the sub-G1 and aneuploid (>4N) populations were analyzed by flow 
cytometry. Following CCT244747 and RT double therapy, there was a significant 
increase in the sub-G1 population in T24 and RT112 cells (Fig 2a).  Although 
aneuploidy was increased following RT, addition of CCT244747 did not further increase 
the percentage of aneuploid cells present 48 hours after therapy (Fig 2a).  
 
CCT244747 and RT combination therapy induces the formation of abnormal 
nuclei 
To investigate changes in nuclear and cell morphology following RT and CCT244727, 
cells were stained with ɣ-H2AX and α-tubulin and analyzed by confocal microscopy. 
Untreated control cells had mainly normal nuclei (normal size and without micronuclei 
(Fig S3a, b)) containing few ɣ-H2AX foci (Fig. 2c). Cells treated with CCT244747 alone 
had mostly normal nuclear morphology, but there was an increase in the percentage of 
nuclei containing ɣ-H2AX foci (Fig S3b) or exhibiting pan-H2AX (Fig S3b) staining. As 
expected, RT increased the number of ɣ-H2AX foci, and significantly increased the 
percentage of cells with abnormal nuclear morphology (Fig S3b). CCT244747 and RT 
combination caused a further increase in the number of cells with abnormal nuclear 
morphology, either due to an increase in multinucleation or the presence of micronuclei 
(Fig 2c, S3a), suggesting cells were undergoing mitotic catastrophe. The percentage of 
cells with ɣ-H2AX nuclear staining (foci, pan, foci + abnormal, pan + abnormal) was 
significantly increased for all cell lines.  
To further assess whether cells were undergoing apoptosis, cell lysates were collected 
24 and 48 hours after treatment and analyzed for Caspase-3 and PARP cleavage by 
Western blotting. Single-agent CCT244747 increased cleaved PARP levels in T24 and 
Cal 27 at 24 hours and in all three cell lines at 48 hours.  This was accompanied by an 
increase in cleaved Caspase-3 levels in T24 and Cal 27 at 48 hours.  Radiotherapy 
increased PARP and Caspase-3 cleavage in T24 and RT112 but not Cal27 at 48 hours.  
In T24 and Cal27, combination therapy did not result in a further increase in Caspase-3 
or PARP cleavage (Fig 2d). RT112 cells, showed increased PARP and Caspase-3 
cleavage with combination therapy. 
In vivo radiosensitization by CCT244747 
We tested the effect of CCT244747, either alone or in combination with RT, in Cal27 
xenografts in vivo (Fig. 3a). We did not observe any clinical signs of toxicity (including a 
less than 5% drop in body weight) in all 4 treatment groups. The average tumour 
volume, which was between 70 and 90 mm3 at day 0, reached 1061 mm3 in the control 
group after 70 days (Fig. 3b). The increase in volume was less evident in the drug alone 
and RT alone groups compared to the controls (910 vs 879 vs 1061 mm).  The mean 
tumour volume in the combination therapy group at 70 days was significantly lower than 
either drug or radiotherapy alone groups (445 mm3; P<0.05 for both).  It took 35.4±9.6 
days for the tumours in the combination treatment group to reach a minimum of 3 times 
their original volume. In contrast, it took 19.9±3.5 days in the radiation alone group, 
24.7±8.3 days in the CCT244747 alone group and 20±3 days in the control group to 
reach this size.    
The median survival data reflected the lower tumour burden in the combination group 
compared with the others (Fig. 3c). Median survival values increased from 40 days 
(control and RT alone), to 58 days (drug only) and Not Reached (RT plus CCT244747) 
(P<0.01 vs all other treatment groups). Indeed, the combination group recorded 75% 
survival at 70 days, having achieved a stable average tumour volume of 450 mm3. The 
combination of RT and CCT244747 was significantly different from the single treatments 
(P=0.0042) (log-rank Mantel-Cox test).   
 
 
 
Discussion 
Cytotoxic chemotherapy is combined with radiotherapy to treat muscle invasive bladder 
cancers and locally advanced HNSCC, allowing organ preservation [13-15].  Due to the 
associated side-effects and poor outcomes, there is a need for less toxic and more 
effective treatments.  Pre-clinical studies have evaluated several novel radiosensitisers 
in bladder cancer models [16-19], but no agent has translated into clinical trials 
reporting improved outcomes.       
The current study confirms previously published work regarding the role of Chk1 in 
mediating tumour radioresistance [20].  This study demonstrated that the orally active 
Chk1 inhibitor CCT244747 radiosensitised tumour cells both in vitro and in vivo, and the 
combination demonstrated growth delay in a cancer xenograft model with a survival 
benefit. Radiosensitization was elicited through abrogation of RT-induced G2 cell cycle 
arrest, forcing cells into premature mitosis with unrepaired DNA-DSBs.  Although 
previously described in pre-clinical head and neck cancer models [7], to our knowledge, 
this is the first study showing Chk1-mediated radiosensitization in bladder cancer cells.     
Most cancer cells are more dependent than normal cells on the G2 checkpoint to repair 
DNA damage, because of a deficient G1 checkpoint [21]. Targeting the G2 checkpoint 
as an anticancer strategy has been explored as monotherapy [22] or in combination 
with DNA damaging agents [23].  Following DNA damage, Chk1 inhibition prevents G2 
arrest forcing cells into premature M phase and cell death by mitotic catastrophe and/or 
apoptosis [7].   
In addition to cellular signaling, the efficacy of the combination treatment is dependent 
on cell cycle perturbation. As demonstrated previously, Chk1 inhibition was able to 
overcome RT-mediated G2 arrest, causing cells to prematurely enter mitosis.  We also 
observed a decrease in the S phase of the cell cycle 24 hours after RT, which was 
abrogated in cells treated with CCT244747/RT combination therapy. Western analysis 
confirmed these changes in the cell cycle and also indicated that, despite unrepaired 
DNA DSBs remaining at 24 and 48 hours after CCT244747/RT therapy, cells were still 
entering mitosis (evidenced by the expression of p-HH3) and, therefore, were likely to 
undergo mitotic catastrophe.  
It has previously been shown that Chk1 inhibition during DNA replication can lead to 
disruption of the normal repair and restart pathways following stalled replication forks [3, 
12, 24]. This can manifest as pan-nuclear H2AX staining, which has been linked to 
replication stress, S phase arrest [25] and apoptosis [12]. Indeed, our analysis revealed 
that cells treated with CCT244747/RT combination therapy exhibited increased pan-
nuclear H2AX staining and abnormal nuclei, which resulted in apoptosis.  Cells with 
pan-nuclear H2AX staining following RT alone may represent cells with foci alone, as 
this population was reduced after the combination of CCT24474 and RT.   
PARP facilitates cellular disassembly and, following cleavage by Caspase-3, serves as 
a marker of cells undergoing apoptosis at later time points.  CCT244747 increased 
cleaved PARP levels at 24 and 48 hours, whilst radiotherapy increased cleaved PARP 
levels at 48 hours.  CCT244747 appeared to induce apoptotic cell death 24 hours 
earlier than radiotherapy.  The mode of cell death following irradiation is dependent on 
several factors including the cell type and we note Cal 27 cells did not undergo 
apoptosis following radiotherapy alone.     
Our in vivo model confirmed the in vitro findings and showed that CCT244747 
radiosensitizes tumour cells. CCT244747 and RT monotherapies had modest effects on 
tumour growth, whereas the combination treatment demonstrated a significant tumour 
growth delay that translated into improved survival of the CCT244747 plus RT group. 
Based on these data, it will be important to investigate the combination of CCT244747 
and radiation in early phase clinical trials in an attempt to develop efficacious treatments 
with less toxicity than conventional CRT.  
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Figures 
 
Fig. 1. CCT244747 increases the sensitivity of T24, RT112 and Cal27 cancer cell 
lines to radiation.(a) Clonogenic survival of T24, RT112 and Cal27 cancer cells  
and hTert RPE1 epithelial cell lines following CCT244747 treatment (solid line), 
or  CCT244747 combined with radiation treatment (dashed line). Data 
normalised to untreated control or CCT244747 only results and presented as 
mean±SEM of at least 3 individual experiments. * = P<0.05, ** = P<0.01, *** = 
P<0.001. (b) Western blots of lysates from T24, RT112 and Cal27 cells treated 
with CCT244747, RT, or a combination of both (CCT244747 and RT) 
demonstrating drug-on-target effect for each cell line used. Cells were collected 8 
and 12 hours after CCT244747 exposure. 
 
 
  
Fig. 2. CCT244747 abrogates the RT-induced G2 arrest and drives premature 
mitotic entry.  
 T24, RT112 and Cal27 were treated with radiation 6 hours after administration of 
CCT244747.  (a)Relative change to various phases of the cell cycle at 12, 24 and 
48 hour time-points following exposure to CCT244747. DNA content and Mitotic 
index were assessed by flow cytometry using propidium iodide and pS10-histone 
H3. Data are normalised to the untreated ‘control’ samples and presented as the 
mean ± SEM of 3 independent experiments.  * = P<0.05, ** = P<0.01, *** = 
P<0.001. (b) Western blot showing cell cycle progression markers (pHH3) and 
DNA damage marker (ɣ-H2AX). (c)  Quantification of immunofluorescent images 
from cells fixed 24 hours after treatment with CCT244747; positive for foci when 
≥5 foci; positive for pan-nuclear staining when ≥80% of the nucleus was stained 
positive for (ɣ-H2AX) and cells with micronuclei and multinucleated cells were 
considered as abnormal nuclei. (d) Western blot showing apoptotic markers 
PARP-1 and caspase-3 at 24 and 48 hours. 
 
 
 
 
Fig. 3. CCT244747 is an in vivo radiosensitizer. Athymic nude mice were injected 
subcutaneously with 3x106 Cal27 cells and divided in 4 groups. Mice were 
treated with CCT244747 (100 mg/kg) by gavage 1h prior to RT (2 Gy x 5). (a) 
Schematic representation of the schedule used to treat the mice. (b) Tumour 
growth delay (mean ± SD) and (c) survival. 
 
 
  
Fig. S1. Dose modifying Factor of CCT244747 
Cells were treated with 2 µM of CCT244747 6 hours before being given different 
doses of radiation. (a) Curves normalized to 0 Gy radiation with or without drug. 
(b) Table showing the DMF extrapolated from the curves in (a). D0 is the dose of 
radiation needed for the surviving fraction to be 0.37. 
 
  
Fig. S2. Flow cytometry data 
G1 and S phase populations at 12 and 24 hours post treatment with CCT244747.  
 
 
  
Fig. S3. Representative images  
Cells were treated with 4 Gy 6 hours after CCT244747 administration and fixed 
24 hours after treatment. Representative images (a) of the immunofluorescence 
assay showing DNA (blue), (ɣ-H2AX (green) and tubulin (red); (b) normal nuclei, 
nuclei with ɣ-H2AX foci, pan-nuclear ɣ-H2AX staining, multinucleated cells and 
cell with micronuclei.  
 
 
